Carole Faig is an experienced public and private company board member. Prior to her retirement, she was a recognized leader in the US Health industry. As EY’s US Health leader from 2017 to 2020, Carole was responsible for developing and driving EY’s strategy to grow its health care practice in a rapidly changing environment. Under her leadership, EY’s health practice, including healthcare services and health insurance, grew to $600M and gained improved brand recognition in the market. Additionally, during her career at EY, Carole was an audit partner serving health systems, health insurers, biotech and medtech companies. She is qualified to serve as a financial expert under SEC, NYSE and NASDAQ rules. Carole retired from EY in July 2021, with more than 38 years of audit and public accounting experience.
As EY’s US Health leader, Carole helped companies navigate the rapidly evolving health ecosystem, specifically in the areas of convergence, optimization and growth, digital transformation, and risk and regulatory matters. Her experience includes all sectors of health, including hospital systems, health insurance, biotechnology and medical device companies. Carole hosted roundtables and panels for leaders of the health care industry including the Digital Health Summit, a part of Consumer Electronics Show and the Healthcare Financial Management Association. During the COVID 19 pandemic, Carole was involved in formulating EY’s perspectives on employee health and safety as well as enterprise resiliency and financial recovery.
Concurrent with her US Health Leadership role, Carole also served as the leader of EY’s West Region Health and Life Sciences $500 million market segment. As Market Segment Leader, Carole spearheaded EY’s efforts to bring the full strength of its services - audit, tax, M&A and business consulting services to health and life sciences companies across the region in addition to managing the segment’s operations including revenue forecasts, operating results and headcount. Additionally, Carole gained extensive experience managing teams including performance reviews, career growth and promotions.
In addition to her market leadership roles in EY’s Health and Life Sciences sector, Carole served as an audit partner. Her clients included large, integrated not-for-profit health systems, public and private health insurance companies as well as early-stage biotech companies. In this role, she advised her clients on accounting and financial reporting matters including complex accounting issues and internal controls. Carole assisted companies
with tax-exempt financings and IPOs working closely with investment bankers, underwriters and legal counsel.
Additionally, Carole has extensive experience presenting complex and challenging issues to the Boards of Directors and Audit committees. Carole sits on the Board of Directors of Henry Schein (HSIC), a FORTUNE 500 Company and a member of the S&P 500®. In addition, she serves on the board of two private VC/PE-backed companies, Affinia Therapeutics and QuVa Pharma as well as two non-profit organizations, PATH, focused on global health
and SCAN Group, a Medicare advantage health plan.
Throughout her professional career, Carole has been recognized for her leadership on matters related to diversity and inclusiveness. She served on EY’s Gender Equity Task Force focused on bringing gender equity to the forefront at EY. In recognition of her dedication to building an inclusive workplace, Carole was awarded EY’s Chairman’s Value Award and EY Americas Assurance Inclusive Leadership Award.
Carole is a 1983 graduate of Sam Houston State University. She is a CPA having earned her CPA license in 1986. She and her husband, Robert Sullivan, split time between their home in Colorado and their travels
Sign in to Patient Account